338 related articles for article (PubMed ID: 24073949)
1. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Boston University staging system in AL amyloidosis.
Tomlinson R; Matigian N; Mollee P
Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
[No Abstract] [Full Text] [Related]
4. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
[TBL] [Abstract][Full Text] [Related]
5. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
Zaroui A; Kharoubi M; Gounot R; Oghina S; Degoutte C; Bezard M; Galat A; Guendouz S; Roulin L; Audard V; Leroy V; Teiger E; Poullot E; Molinier-Frenkel V; Le Bras F; Belhadj K; Bastard JP; Fellahi S; Shourick J; Lemonier F; Damy T
ESC Heart Fail; 2024 Jun; 11(3):1707-1719. PubMed ID: 38444090
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
7. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
Dispenzieri A; Gertz MA; Kumar SK; Lacy MQ; Kyle RA; Saenger AK; Grogan M; Zeldenrust SR; Hayman SR; Buadi F; Greipp PR; Leung N; Russell SR; Dingli D; Lust JA; Rajkumar SV; Jaffe AS
Heart; 2014 Mar; 100(5):383-8. PubMed ID: 24402772
[TBL] [Abstract][Full Text] [Related]
8. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
11. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.
Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L
BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398
[TBL] [Abstract][Full Text] [Related]
12. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of novel biomarkers in patients with AL amyloidosis.
Kim D; Lee GY; Choi JO; Kim K; Kim SJ; Ju ES; Jeon ES
Sci Rep; 2019 Aug; 9(1):12200. PubMed ID: 31434944
[TBL] [Abstract][Full Text] [Related]
14. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
[TBL] [Abstract][Full Text] [Related]
15. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
Palladini G; Barassi A; Klersy C; Pacciolla R; Milani P; Sarais G; Perlini S; Albertini R; Russo P; Foli A; Bragotti LZ; Obici L; Moratti R; Melzi d'Eril GV; Merlini G
Blood; 2010 Nov; 116(18):3426-30. PubMed ID: 20644111
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
17. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis.
Vergaro G; Castiglione V; Aimo A; Prontera C; Masotti S; Musetti V; Nicol M; Cohen Solal A; Logeart D; Georgiopoulos G; Chubuchny V; Giannoni A; Clerico A; Buda G; Patel KN; Razvi Y; Patel R; Wechalekar A; Lachmann H; Hawkins PN; Passino C; Gillmore J; Emdin M; Fontana M
Eur J Heart Fail; 2023 Mar; 25(3):335-346. PubMed ID: 36597836
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
19. Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.
Kristen AV; Rinn J; Hegenbart U; Lindenmaier D; Merkle C; Röcken C; Hardt S; Giannitsis E; Katus HA
Clin Res Cardiol; 2015 Mar; 104(3):250-7. PubMed ID: 25331161
[TBL] [Abstract][Full Text] [Related]
20. Impaired right ventricular function as a predictor of early mortality in patients with light‑ chain cardiac amyloidosis assessed in a cardiology department.
Szczygieł JA; Wieczorek PZ; Drozd-Sokołowska J; Michałek P; Mazurkiewicz Ł; Legatowicz-Koprowska M; Walczak E; Jędrzejczak WW; Dwilewicz-Trojaczek J; Grzybowski J
Pol Arch Intern Med; 2017 Dec; 127(12):854-864. PubMed ID: 29112180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
